CSL Ltd (CSL) discovers, develops, manufactures, commercializes and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of hemophilia, hereditary angioedema, von Willebrand disease, inherited primary and secondary immune deficiencies, respiratory disease, neurological disorders and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns, infection in solid organ transplant recipients and to treat specific infections for victims of trauma and burns. CSL markets an array of vaccines, anti-venoms and pharmaceutical products of various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the US, the UK and other countries. CSL is headquartered in Parkville, Victoria, Australia.
Headquarters
Australia
Address
45 Poplar Road, Parkville, Melbourne, Victoria, 3052
Website
www.csl.com
Telephone
61 3 93891911
No of Employees
30,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CSL (ASX)
Revenue (2022)
$10.6B
2.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-5.1%
(2022 vs 2021)
Market Cap*
$99.1B
Net Profit Margin (2022)
XYZ
-7.3%
(2022 vs 2021)
* As of and is in US$
CSL Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Plasma-derived Therapies |
| Vaccines |
| Diagnostics Products |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Corporate Changes/Expansions | In March, the company opened a new state-of-the-art research and development (R&D) center in Waltham, Massachusetts. |
| 2023 | Contracts/Agreements | In February, CSL Seqirus and Amarin entered into a license and distribution agreement under which Amarin will license exclusive rights to VAZKEPA to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand. |
| 2023 | Contracts/Agreements | In February, the company along with UniQure NV announced the publication in the New England Journal of Medicine of results from the pivotal HOPE-B clinical study evaluating the efficacy, durability and safety of HEMGENIX. |
Competitor Comparison
| Key Parameters | CSL Ltd | AbbVie Inc | Bayer AG | Bristol-Myers Squibb Co | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | Australia | United States of America | Germany | United States of America | United Kingdom |
| City | Melbourne | North Chicago | Leverkusen | New York | Cambridge |
| State/Province | Victoria | Illinois | Nordrhein-Westfalen | New York | England |
| No. of Employees | 30,000 | 50,000 | 101,735 | 34,300 | 83,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Brian McNamee | Chairman | Executive Board | 2018 | 64 |
| Paul McKenzie | Chief Executive Officer; Managing Director | Senior Management | 2023 | - |
| Joy Linton | Chief Financial Officer | Senior Management | 2020 | 55 |
| Bill Mezzanotte, M.D. | Chief Medical Officer; Executive Vice President; Head - Research & Development | Senior Management | 2020 | 62 |
| Andrew Cuthbertson, Ph.D. | Executive Director | Senior Management | 2018 | 66 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward